Target/Analyte:
T+TGF-β1, SF / MCP-1

Short Name T+TGF-β1, SF / MCP-1
Description The TC+TGF-β1 treatment group is comprised of tenocytes in the collagen hydrogel cultured for 7 days and exposed with TGF-β1 at 10 ng/mL. No top component is attached. The MCP-1 cytokine subjected to this treatment is a key chemokine that regulates migration and infiltration of monocytes and macrophages.

Method/Kits with this Target/Analyte
Method/Kit Description
Luminex Human Discovery Assay (8-Plex) LXSAHM-08 The Luminex Assay is a bead-based immunoassay multiplex technique that allows multiple analytes (ex. cytokines, chemokines, metabolic biomarkers, etc.) to be quantitated simultaneously in a single biological matrix sample. Generally, the results obtained using a standardized Luminex assay are superior or equivalent to conventional ELISA, even as the differentiated xMAP technology allows high throughput biomarker testing with reduced sample volume, test preparation, and reagent costs. Luminex immunoassays can multiplex up to 100 compatible analytes simultaneously using a commercial or custom kit. The 8-Plex quantitates 8 analytes simultaneously and was used for the hToc experiment at CMSR @ UR. CMSR @ UR chose the 8 cytokines (Monocyte Chemoattractant Protein-1, Interleukin 6, C-C Motif Chemokine Ligand 3, Interleukin 10, C-X-C Motif Chemokine Ligand 10, Interleukin 1 beta, Tumor necrosis Factor alpha, Interleukin 17) to test the cell supernatant of our top well at different time points and culture conditions.

Studies Utilizing this Target/Analyte
Study Start Date Study Types Description
Loading...